Opinion
Video
Comprehensive Molecular Testing in Patients With Ovarian Cancer
Author(s):
A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a timely manner for patients with ovarian cancer, emphasizing the need for better education of health care providers and more affordable, widely available testing options.
Video content above is prompted by the following:
Challenges in Comprehensive Molecular Testing
Two primary barriers impact comprehensive molecular testing implementation:
Education:
- Physicians need better awareness about which tests to order, when to order them, and how to interpret results.
- All patients with advanced or recurrent disease should receive comprehensive testing (DNA, RNA, and protein analysis).
- Education must extend to health care providers, patients, and the broader community.
Cost and reimbursement:
- Medicare covers several biomarker tests with little to no patient cost.
- Reimbursement varies by insurance type, with inconsistencies in federal and state funding.
- Improving value requires both better education and more affordable testing options.
Addressing these barriers would support wider adoption of comprehensive molecular testing in ovarian cancer.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
